Halozyme’s Spotlight Shifts To Enhanze Exclusively After PEGPH20 Fails In Phase III

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

The Enhanze drug delivery technology, which is expected to be profitable starting next year, takes center stage as Halozyme discontinues PEGPH20 development and cuts its oncology operations along with 160 jobs.

SC1911_Spotlight_76770868_1200.jpg
After 160 job cuts and with an Enhanze-only focus, Halozyme will be profitable next year. • Source: Shutterstock

Halozyme Therapeutics Inc.’s only clinical drug candidate PEGPH20 will exit the stage – along with the company’s oncology operations – now that the drug has failed to show an improvement in overall survival versus the standard of care in pancreas cancer in the Phase III HALO-301 clinical trial. The spotlight now will focus entirely on the Enhanze drug delivery platform as Halozyme restructures to support its existing partners, including two with product approvals anticipated next year.

The San Diego-based company announced on 4 November that while first-line treatment with PEGPH20 in combination with Celgene Corp.’s...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

Scrip-Business (Free-1): Top-Selling Drugs 2024: Keytruda, Ozempic And Dupixent Dominate

 
• By Nabil

Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.

Ordspono Will Be Regeneron’s First Independent European Launch

 
• By Jessica Merrill

Ordspono, a bispecific antibody newly approved in the EU to treat follicular lymphoma and diffuse large B-cell lymphoma, joins Libtayo in Regeneron’s growing oncology portfolio.

Galderma Gets First Biologic To Market With Nemluvio Approval

 
• By Jessica Merrill

Nemluvio is a first-in-class IL-31 inhibitor that the US FDA approved for prurigo nodularis. 

Kerendia Could Be Next Jewel In Bayer's Pharma Crown

 
• By Kevin Grogan

CEO Bill Anderson would not be drawn on whether the drug, currently approved for chronic kidney disease associated with type 2 diabetes, will hit a previous forecast of €3bn peak sales, but expansion into heart failure may make that figure look conservative.

More from Business

How A New Healthcare Dialogue Is Driving Market Access In Mexico

Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.